Blood:VIII因子在内质网中形成可逆性的淀粉样蛋白

2020-03-05 QQY MedSci原创

中心点:FVIII在ER中形成淀粉样聚积物,并以伴蛋白和葡萄糖依赖的方式溶解,从而产生分泌型功能性FVIII。A1结构域中的一个短链氨基酸模体启动β-sheet聚合,ER伴侣蛋白BiP与该模体结合可防止聚合。摘要:A型血友病,一种X染色体连锁的出血性疾病,由VIII因子(FVIII)缺陷引起的,采用蛋白替代疗法治疗。不幸的是,由于重组FVIII是由哺乳动物宿主细胞分泌的低水平分泌产物,因此该方案成

中心点:

FVIII在ER中形成淀粉样聚积物,并以伴蛋白和葡萄糖依赖的方式溶解,从而产生分泌型功能性FVIII。

A1结构域中的一个短链氨基酸模体启动β-sheet聚合,ER伴侣蛋白BiP与该模体结合可防止聚合。

摘要:

A型血友病,一种X染色体连锁的出血性疾病,由VIII因子(FVIII)缺陷引起的,采用蛋白替代疗法治疗。不幸的是,由于重组FVIII是由哺乳动物宿主细胞分泌的低水平分泌产物,因此该方案成本较高。FVIII表达激活内质网应激反应,引起氧化应激,诱导细胞凋亡。重要的是,在多细胞动物中,引起蛋白错误折叠和聚合的因素知之甚少。

在本研究中,研究人员发现了导致FVIII形成聚集物的内在和外在因素。当FVIII合成增加或葡萄糖代谢受到抑制时,FVIII会在内质网中形成淀粉样原纤维。值得注意的是,在葡萄糖代谢恢复后,FVIII淀粉样蛋白可以溶解,并产生功能性的分泌FVIII。

两个ER伴侣蛋白家族和他们的共同伴侣蛋白BiP和CANX/CRT,促进了FVIII在ER中的溶解,而前者也需要被降解。FVIII A1结构域的一个短的聚合模体(称为Aggron),对b-sheet聚合是必不可少的,也是足够的,BiP与Aggron结合可以防止淀粉样发生。

总而言之,本研究为限制FVIII分泌和ER蛋白聚合的一般机制提供了新的见解,并对正在进行的A型血友病基因疗法临床试验具有意义。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916243, encodeId=b94119162431f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue May 26 10:01:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668832, encodeId=83cf166883282, content=<a href='/topic/show?id=fdea18432f3' target=_blank style='color:#2F92EE;'>#VIII因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18432, encryptionId=fdea18432f3, topicName=VIII因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa4f26457969, createdName=liye789132260, createdTime=Sat Nov 21 08:01:00 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442865, encodeId=cb581442865e7, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580254, encodeId=eba4158025451, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-05-26 juliusluan78
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916243, encodeId=b94119162431f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue May 26 10:01:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668832, encodeId=83cf166883282, content=<a href='/topic/show?id=fdea18432f3' target=_blank style='color:#2F92EE;'>#VIII因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18432, encryptionId=fdea18432f3, topicName=VIII因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa4f26457969, createdName=liye789132260, createdTime=Sat Nov 21 08:01:00 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442865, encodeId=cb581442865e7, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580254, encodeId=eba4158025451, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1916243, encodeId=b94119162431f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue May 26 10:01:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668832, encodeId=83cf166883282, content=<a href='/topic/show?id=fdea18432f3' target=_blank style='color:#2F92EE;'>#VIII因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18432, encryptionId=fdea18432f3, topicName=VIII因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa4f26457969, createdName=liye789132260, createdTime=Sat Nov 21 08:01:00 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442865, encodeId=cb581442865e7, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580254, encodeId=eba4158025451, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1916243, encodeId=b94119162431f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue May 26 10:01:00 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668832, encodeId=83cf166883282, content=<a href='/topic/show?id=fdea18432f3' target=_blank style='color:#2F92EE;'>#VIII因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18432, encryptionId=fdea18432f3, topicName=VIII因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa4f26457969, createdName=liye789132260, createdTime=Sat Nov 21 08:01:00 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442865, encodeId=cb581442865e7, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580254, encodeId=eba4158025451, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Sat Mar 07 13:01:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]

相关资讯

Blood:降低V因子的水平可改善缺乏V因子和VIII因子患者的出血症状

FV和FVIII共缺乏症(F5F8D)是一种罕见的由LMAN1和MCFD2突变引起的常染色体隐性出血性疾病。研究人员在6位F5F8D患者中发现了6种不同的纯合致病突变(LMAN1中5种,MCFD2中1种)。但矛盾的是,在F5F8D血浆中,用1 pM TF触发凝血酶生成试验显示凝血酶生成较正常血浆的增强。与健康对照组相比,F5F8D患者的自由组织因子途径抑制剂(fTFPI)显著降低。正常化F5F8D

Blood:FVIII-纳米抗体融合蛋白与VWF形成稳定的相互作用,可延长FVIII的作用时间、减弱FVIII的免疫反应

中心点:VIII因子与抗VWF纳米抗体融合可增强VWF的亲和力,高达25倍,而且不影响FVIII活性。稳定的VWF结合可使FVIII的循环存活率提高达2倍,并可减少抗FVIII抗体的产生。摘要:血管性血友病因子(VWF)调节VIII因子(FVIIII)的清除和抗FVIII免疫反应。虽然FVIII/VWF相互作用具有高亲和力,但结合和解离动力学显示有2-5%的FVIII处于游离状态。为了避免在体内研

Blood:VWF清除和FVIII结合的遗传决定因素修饰血友病患者的FVIII药代动力学

在A型血友病患者中,VIII因子(FVIII)的药代动力学特性显示出高度的患者间变异性。虽然既往研究表明年龄、体重指数、VWF抗原水平和ABO血型状况都会影响FVIII的药代动力学,但它们并不能解释所有观察到的差异。在本研究中,研究人员对43名A型血友病患儿的FVIII药物代谢动力学特征的遗传决定因素进行分析。

Blood:BIVV001,一种新型FVIII替代品,用于A型血友病的止血控制效果!

中心点:BIVV001是一种新型的融合蛋白,在A型血友病临床前模型中的止血控制效果与rFVIII高4倍。BIVV001有潜力为重度A型血友病患者提供针对所有出血类型的更优、更广泛的保护。摘要:FVIII的替代产品为A型血友病患者提供全面的防护。重度A型血友病的治疗目标正在扩大,不再局限于降低年化出血率,还包括与持续高FVIII水平相关的长期预后。虽然内源性VWF可稳定保护FVIII免于降解和清除,